AstraZeneca (AZN) Misses Q2 EPS by 7c; Raises FY11 EPS Outlook; Recommends Dividend; Potential Increase in Buybacks
Tweet
Share
E-mailGet Alerts AZN Hot Sheet
Join SI Premium – FREE
AstraZeneca (NYSE: AZN) reported Q2 EPS of $1.73, $0.07 worse than the analyst estimate of $1.80. Revenue for the quarter came in at $8.43 million versus the consensus estimate of $8.19 billion.
AstraZeneca sees FY2011 EPS of $7.05-$7.35, versus the consensus of $7.15.
The Board has recommended a first interim dividend of $0.85. Net share repurchases totalled $2.2 billion in the first half. When completed, the entire net proceeds from the sale of Astra Tech will augment share repurchases; depending on the timing, net share repurchases in 2011 could increase to $5 billion.
AstraZeneca sees FY2011 EPS of $7.05-$7.35, versus the consensus of $7.15.
The Board has recommended a first interim dividend of $0.85. Net share repurchases totalled $2.2 billion in the first half. When completed, the entire net proceeds from the sale of Astra Tech will augment share repurchases; depending on the timing, net share repurchases in 2011 could increase to $5 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
- Lifevantage (LFVN) Declares $0.050 Quarterly Dividend; 3% Yield
Create E-mail Alert Related Categories
Dividends, Earnings, Guidance, Stock BuybacksRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
